Tarsus Pharmaceuticals Analyst Ratings
Tarsus Pharmaceuticals Analyst Ratings
While ratings are subjective and will change, the latest Tarsus Pharmaceuticals (TARS) rating was a initiated with a price target of $0.00 to $19.00. The current price Tarsus Pharmaceuticals (TARS) is trading at is $18.86, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 0.74% | Goldman Sachs | → $19 | Initiates Coverage On | → Neutral |
| 11/10/2023 | 165.11% | HC Wainwright & Co. | $42 → $50 | Maintains | Buy |
| 09/11/2023 | 159.81% | Guggenheim | $46 → $49 | Maintains | Buy |
| 08/14/2023 | 143.9% | Guggenheim | → $46 | Reiterates | Buy → Buy |
| 08/11/2023 | 122.69% | HC Wainwright & Co. | $50 → $42 | Maintains | Buy |
| 07/26/2023 | 165.11% | HC Wainwright & Co. | $44 → $50 | Maintains | Buy |
| 07/18/2023 | 133.3% | William Blair | → $44 | Initiates Coverage On | → Outperform |
| 06/26/2023 | 133.3% | HC Wainwright & Co. | $40 → $44 | Maintains | Buy |
| 06/16/2023 | 122.69% | Guggenheim | $40 → $42 | Maintains | Buy |
| 05/18/2023 | — | Guggenheim | Initiates Coverage On | → Buy | |
| 05/08/2023 | 128% | Oppenheimer | → $43 | Reiterates | → Outperform |
| 03/15/2023 | 112.09% | HC Wainwright & Co. | → $40 | Reiterates | → Buy |
| 08/01/2022 | 112.09% | Barclays | → $40 | Initiates Coverage On | → Overweight |
| 12/21/2021 | 112.09% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 11/23/2021 | 191.62% | Oppenheimer | → $55 | Initiates Coverage On | → Outperform |
| 10/08/2021 | 244.64% | Raymond James | $50 → $65 | Maintains | Strong Buy |
| 06/29/2021 | 165.11% | Raymond James | $39 → $50 | Maintains | Strong Buy |
| 11/10/2020 | 122.69% | Ladenburg Thalmann | → $42 | Initiates Coverage On | → Buy |
| 11/10/2020 | 74.97% | B of A Securities | → $33 | Initiates Coverage On | → Buy |
| 11/10/2020 | 85.58% | Jefferies | → $35 | Initiates Coverage On | → Buy |
| 11/10/2020 | 106.79% | Raymond James | → $39 | Initiates Coverage On | → Strong Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/20/2023 | 0.74% | 高盛 | → 19 美元 | 启动覆盖范围开启 | → 中立 |
| 11/10/2023 | 165.11% | HC Wainwright & Co. | 42 美元 → 50 美元 | 维护 | 买 |
| 09/11/2023 | 159.81% | 古根海姆 | 46 美元 → 49 美元 | 维护 | 买 |
| 08/14/2023 | 143.9% | 古根海姆 | → 46 美元 | 重申 | 购买 → 购买 |
| 08/11/2023 | 122.69% | HC Wainwright & Co. | 50 美元 → 42 美元 | 维护 | 买 |
| 07/26/2023 | 165.11% | HC Wainwright & Co. | 44 美元 → 50 美元 | 维护 | 买 |
| 07/18/2023 | 133.3% | 威廉布莱尔 | → 44 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 06/26/2023 | 133.3% | HC Wainwright & Co. | 40 美元 → 44 美元 | 维护 | 买 |
| 06/16/2023 | 122.69% | 古根海姆 | 40 美元 → 42 美元 | 维护 | 买 |
| 05/18/2023 | — | 古根海姆 | 启动覆盖范围开启 | → 购买 | |
| 05/08/2023 | 128% | 奥本海默 | → 43 美元 | 重申 | → 跑赢大盘 |
| 03/15/2023 | 112.09% | HC Wainwright & Co. | → 40 美元 | 重申 | → 购买 |
| 08/01/2022 | 112.09% | 巴克莱 | → 40 美元 | 启动覆盖范围开启 | → 超重 |
| 12/21/2021 | 112.09% | HC Wainwright & Co. | → 40 美元 | 启动覆盖范围开启 | → 购买 |
| 11/23/2021 | 191.62% | 奥本海默 | → 55 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 8 月 10 日 | 244.64% | 雷蒙德·詹姆 | 50 美元 → 65 美元 | 维护 | 强势买入 |
| 06/29/2021 | 165.11% | 雷蒙德·詹姆 | 39 美元 → 50 美元 | 维护 | 强势买入 |
| 11/10/2020 | 122.69% | 拉登堡塔尔曼 | → 42 美元 | 启动覆盖范围开启 | → 购买 |
| 11/10/2020 | 74.97% | B of A 类证券 | → 33 美元 | 启动覆盖范围开启 | → 购买 |
| 11/10/2020 | 85.58% | 杰富瑞集团 | → 35 美元 | 启动覆盖范围开启 | → 购买 |
| 11/10/2020 | 106.79% | 雷蒙德·詹姆 | → 39 美元 | 启动覆盖范围开启 | → 强势买入 |
What is the target price for Tarsus Pharmaceuticals (TARS)?
Tarsus Pharmicals（TARS）的目标价格是多少？
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Goldman Sachs on November 20, 2023. The analyst firm set a price target for $19.00 expecting TARS to rise to within 12 months (a possible 0.74% upside). 12 analyst firms have reported ratings in the last year.
高盛于2023年11月20日公布了塔苏斯制药（纳斯达克股票代码：TARS）的最新目标股价。该分析公司将目标股价定为19.00美元，预计TARS将在12个月内升至12个月内（可能上涨0.74％）。去年有12家分析公司公布了评级。
What is the most recent analyst rating for Tarsus Pharmaceuticals (TARS)?
Tarsus Pharmicals（TARS）的最新分析师评级是多少？
The latest analyst rating for Tarsus Pharmaceuticals (NASDAQ: TARS) was provided by Goldman Sachs, and Tarsus Pharmaceuticals initiated their neutral rating.
塔苏斯制药（纳斯达克股票代码：TARS）的最新分析师评级由高盛提供，塔苏斯制药启动了中性评级。
When is the next analyst rating going to be posted or updated for Tarsus Pharmaceuticals (TARS)?
Tarsus Pharmicals（TARS）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tarsus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tarsus Pharmaceuticals was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与塔苏斯制药公司的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。塔苏斯制药的最新评级是在2023年11月20日公布的，因此您应该预计下一个评级将在2024年11月20日左右公布。
Is the Analyst Rating Tarsus Pharmaceuticals (TARS) correct?
分析师对Tarsus Pharmicals（TARS）的评级正确吗？
While ratings are subjective and will change, the latest Tarsus Pharmaceuticals (TARS) rating was a initiated with a price target of $0.00 to $19.00. The current price Tarsus Pharmaceuticals (TARS) is trading at is $18.86, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但塔苏斯制药（TARS）的最新评级是启动的，目标股价为0.00美元至19.00美元。塔苏斯制药（TARS）目前的交易价格为18.86美元，在分析师的预测区间内。